Data gathered: September 22
AI Stock Analysis - aTyr Pharma (ATYR)
Analysis generated September 16, 2025. Powered by Chat GPT.
aTyr Pharma is a biopharmaceutical company dedicated to developing innovative medicines based on novel biological pathways. The company's focus is on leveraging its understanding of extracellular enzyme immunosuppressant therapies to treat various diseases, providing unique therapeutic avenues. aTyr Pharma's research and development pipeline reflects its commitment to addressing significant unmet medical needs.
Stock Alerts - aTyr Pharma (ATYR)
 |
aTyr Pharma | September 19 Price is down by -7.3% in the last 24h. |
|
aTyr Pharma | September 17 Price is down by -6.5% in the last 24h. |
|
aTyr Pharma | September 16 Price is up by 6.9% in the last 24h. |
|
aTyr Pharma | September 16 Reddit mentions are up by 651% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for aTyr Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 85 | Sign up | Sign up | Sign up |
| Webpage traffic | 26,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 13 | Sign up | Sign up | Sign up |
| Facebook Followers | 166 | Sign up | Sign up | Sign up |
| Instagram Followers | 104 | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,502 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,899 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,519 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 81 | Sign up | Sign up | Sign up |
About aTyr Pharma
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
| Price | $1.05 |
| Target Price | Sign up |
| Volume | 21,350,000 |
| Market Cap | $97M |
| Year Range | $0.99 - $6.61 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 22 - GlobeNewswire |
|
 |
Goldman Sachs Group Inc. Acquires 120,496 Shares of aTyr Pharma, Inc. $ATYRSeptember 22 - ETF Daily News |
|
FY2025 EPS Estimates for aTyr Pharma Increased by AnalystSeptember 19 - ETF Daily News |
|
Leerink Partnrs Lowers Earnings Estimates for aTyr PharmaSeptember 19 - ETF Daily News |
 |
aTyr Pharma (NASDAQ:ATYR) Cut to Hold at Leerink PartnrsSeptember 17 - ETF Daily News |
|
FY2026 EPS Estimates for aTyr Pharma Raised by HC WainwrightSeptember 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 390,000 | -390,000 | -20M | -20M | -0.220 |
| Q1 '25 | 0 | 380,000 | -380,000 | -15M | -15M | -0.170 |
| Q4 '24 | 0 | 180,000 | -180,000 | -15M | -16M | -0.181 |
| Q3 '24 | 0 | 390,000 | -390,000 | -17M | -18M | -0.228 |
| Q2 '24 | 0 | 380,000 | -380,000 | -16M | -17M | -0.226 |
Insider Transactions View All
| Gross Jane A filed to buy 9,750 shares at $4. March 17 '25 |
| DENYES NANCY filed to sell 26,555 shares at $3.8. February 4 '25 |
| Broadfoot Jill Marie filed to sell 31,763 shares at $3.8. February 4 '25 |
Similar companies
Read more about aTyr Pharma (ATYR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of aTyr Pharma?
The Market Cap of aTyr Pharma is $97M.
What is the current stock price of aTyr Pharma?
Currently, the price of one share of aTyr Pharma stock is $1.05.
How can I analyze the ATYR stock price chart for investment decisions?
The ATYR stock price chart above provides a comprehensive visual representation of aTyr Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling aTyr Pharma shares. Our platform offers an up-to-date ATYR stock price chart, along with technical data analysis and alternative data insights.
Does ATYR offer dividends to its shareholders?
As of our latest update, aTyr Pharma (ATYR) does not offer dividends to its shareholders. Investors interested in aTyr Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of aTyr Pharma?
Some of the similar stocks of aTyr Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.